Crossmark

Effectiveness of axicabtagene ciloleucel versus conventional treatments as first-line therapy for high-risk large B-cell lymphoma: an external comparator study

Crossref DOI link: https://doi.org/10.1186/s12885-025-15134-4

Published Online: 2025-10-31

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Kim, Ju Hwan

Bea, Sungho

Choi, Yeeun

Yoon, Sang Eun

Kim, Won Seog

Kim, Seok Jin

Shin, Ju-Young
Funding

Funding for this research was provided by:

Ministry of Health and Welfare (HI22C0999, HE23C002800)

Ministry of Food and Drug Safety (RS-2024-00332632)
License Information

Text and Data Mining valid from 2025-10-31

Version of Record valid from 2025-10-31
More Information

Article History

Received: 13 May 2024

Accepted: 30 September 2025

First Online: 31 October 2025

Declarations

:

: This study was approved by the institutional review board of Samsung Medical Center (IRB No. SMC 2023-02-069), and the board waived the requirement for obtaining informed consent as the study utilized anonymized data. This study was conducted in accordance with the Declaration of Helsinki.

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below